FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
Omeros Corporation announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy.…
Read More...
Read More...